Key result
Rivaroxaban linked to ~29% lower risk of recurrent VTE or bleeding hospitalization vs. LMWH.
Why the study?
Guidelines recommend direct oral anticoagulants as alternatives to LMWH for most patients with cancer-associated venous thromboembolism, but comparative effectiveness and safety data in a broad cohort were needed.
Does rivaroxaban reduce recurrent VTE and bleeding-related hospitalization compared to LMWH in adults with cancer-associated venous thromboembolism?
Cohort (n=4,935)
Yes
Does rivaroxaban reduce recurrent VTE and bleeding-related hospitalization compared to LMWH in adults with cancer-associated venous thromboembolism?
Hazard Ratio: 0.71 (95% CI 0.58–0.87)
Absolute Event Rate: 6.6% vs 9.1%
In a large real-world cohort of patients with active cancer, rivaroxaban use was associated with fewer recurrent VTE cases and similar bleeding-related hospitalizations compared to LMWH.
No takes yet. Share an insight, caveat, or question.
Supports considering rivaroxaban in cancer-associated VTE; leaves open practice change without randomized confirmation.
Caroti et al. (2023) conducted a cohort in Cancer-associated venous thromboembolism (n=4,935). Rivaroxaban vs. Low-molecular-weight heparin (LMWH) was evaluated on Composite of recurrent VTE or bleeding-related hospitalization at 3 months (HR 0.71, 95% CI 0.58-0.87). Rivaroxaban exposure was associated with a 29% reduction in the hazard of the composite outcome of recurrent VTE or bleeding-related hospitalization at 3 months compared to LMWH (HR 0.71, 95% CI 0.58-0.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: